Pharmacokinetic changes during extracorporeal membrane oxygenation: implications for drug therapy of neonates.
about
Innovative clinical trial design for pediatric therapeuticsClinical pharmacology of midazolam in neonates and children: effect of disease-a reviewQuantification of perflutren microsphere contrast destruction during transit through an ex vivo extracorporeal membrane oxygenation circuit.Plasma concentrations of oseltamivir and oseltamivir carboxylate in critically ill children on extracorporeal membrane oxygenation supportPharmacotherapy during pediatric extracorporeal membrane oxygenation: a review.Comparison of methods for intravenous infusion of fat emulsion during extracorporeal membrane oxygenation.Can physicochemical properties of antimicrobials be used to predict their pharmacokinetics during extracorporeal membrane oxygenation? Illustrative data from ovine models.A case of vivax malaria complicated by adult respiratory distress syndrome and successful management with extracorporeal membrane oxygenation.Pharmacokinetics of cefotaxime and desacetylcefotaxime in infants during extracorporeal membrane oxygenation.Pharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunologyASAP ECMO: Antibiotic, Sedative and Analgesic Pharmacokinetics during Extracorporeal Membrane Oxygenation: a multi-centre study to optimise drug therapy during ECMO.The ECMO PK Project: an incremental research approach to advance understanding of the pharmacokinetic alterations and improve patient outcomes during extracorporeal membrane oxygenation.Vancomycin population pharmacokinetics during extracorporeal membrane oxygenation therapy: a matched cohort studyFluconazole loading dose pharmacokinetics and safety in infantsPediatric cardiovascular drug dosing in critically ill children and extracorporeal membrane oxygenationProtein-bound drugs are prone to sequestration in the extracorporeal membrane oxygenation circuit: results from an ex vivo study.Evaluation of furosemide regimens in neonates treated with extracorporeal membrane oxygenation.Extracorporeal life support in pediatric and neonatal critical care: a review.Clinical Pharmacology Studies in Critically Ill Children.The impact of extracorporeal life support and hypothermia on drug disposition in critically ill infants and children.Triazole use in the nursery: fluconazole, voriconazole, posaconazole, and ravuconazoleAn exploratory study with an adaptive continuous intravenous furosemide regimen in neonates treated with extracorporeal membrane oxygenation.Sequestration of drugs in the circuit may lead to therapeutic failure during extracorporeal membrane oxygenationA Population Pharmacokinetic Model for Vancomycin in Adult Patients Receiving Extracorporeal Membrane Oxygenation TherapyA systematic review on pharmacokinetic changes in critically ill patients: role of extracorporeal membrane oxygenation.Clinical pharmacology of the loop diuretics furosemide and bumetanide in neonates and infants.Prediction of morphine clearance in the paediatric population : how accurate are the available pharmacokinetic models?Clinical pharmacology of furosemide in neonates: a review.Population Pharmacokinetics and Dose Optimization of Teicoplanin during Venoarterial Extracorporeal Membrane Oxygenation.Pharmacokinetics of Fentanyl and Its Derivatives in Children: A Comprehensive Review.Pediatric Multiple Organ Dysfunction Syndrome: Promising Therapies.Pharmacokinetics and Dosing of Anti-infective Drugs in Patients on Extracorporeal Membrane Oxygenation: A Review of the Current Literature.Standardized Treatment of Neonatal Status Epilepticus Improves Outcome.Propofol, midazolam, vancomycin and cyclosporine therapeutic drug monitoring in extracorporeal membrane oxygenation circuits primed with whole human bloodPhenobarbital use in an infant requiring extracorporeal membrane life support.Modified surface coatings and their effect on drug adsorption within the extracorporeal life support circuitContinuous-Infusion Etomidate in a Patient Receiving Extracorporeal Membrane Oxygenation.Determinants of drug absorption in different ECMO circuits.Vancomycin Dosing in Pediatric Extracorporeal Membrane Oxygenation: Potential Impacts of New Technologies.In vitro drug adsorption and plasma free hemoglobin levels associated with hollow fiber oxygenators in the extracorporeal life support (ECLS) circuit.
P2860
Q24635308-6921FCF9-B470-4FE0-85B6-9DF185346B9FQ27006333-C21C7E7D-7A99-46F0-85D6-FA9736CCF8A6Q27316284-E820F8C7-4E36-4990-BC1E-72DAA7B4CC97Q28474209-11F941C6-6464-49C4-8093-0614AF226292Q30249512-CB832F6C-8AD1-42AB-8885-ED3FAB0AE789Q30438421-54916BA2-9739-44ED-942C-CD520FC95B22Q31032098-C189490E-7AC1-4D23-8785-C9D2BE531D9FQ33412049-E9D16D8F-22E0-4FAA-8220-A28E7E5E9746Q33826426-28EF7684-CC70-4562-BF33-0F3335B18FBDQ33827819-5A8748B4-5D06-4B2F-87D9-FB8BFFC54AC5Q34494688-B991FEFB-FADC-4060-BF97-2D961742266DQ34630847-03A46ED5-6CC7-4391-94B7-680FA9CE1D94Q34636783-AFADC869-312C-42C7-865A-1FE90A8C2BBFQ34807770-D6A07337-6C54-414C-A3E5-8AEF0B8EAEE6Q35161181-35EDBA7F-2A35-47C5-9678-F54F1DFF1125Q35530267-5BBB2E4B-3800-4D49-AD46-A20E11EA732BQ35629919-506164EB-D0D9-47D6-A72B-A1688C10A709Q35883408-D35D90A3-CE9B-4D88-B39C-B30AEB04E85CQ36120465-88B66246-B975-41E6-8F0A-C930B3C54CA8Q36452379-910D0959-22EA-48BC-ADF5-D49A0378A566Q36521993-8FC26707-D170-41C9-A91D-F82639743528Q36916305-13A5E7D2-A0F3-44FC-8D1B-73C4A6813412Q36928231-386E3090-A00C-47F2-8F7C-A04976D0B3B3Q37283031-CDFA48D5-B002-4AA6-80B7-55EFE9B76641Q38012111-6F148C4E-AA47-4028-8C0E-D7C818E4BA3AQ38019028-E1D9CFB6-ED26-4663-9B76-D57FD90C479CQ38047202-DB992CE4-C8DF-4988-AD3D-23A95B78F609Q38166237-38A3B3B2-FA25-4F8B-A9DC-9516B89264D0Q38374584-2AB9B361-156C-458C-BDE9-45540D66F253Q38688708-40AEE6AF-0769-41DF-99F5-44D2372E4A31Q38751931-F9E22690-500F-404A-B341-6345FBE0E8C6Q38935160-BDA32942-826D-4B4D-9A04-D59B438784CFQ39434365-2AF78BAD-5198-4847-82B2-DA97D692EDCAQ41052029-8B6F645F-470A-4932-B375-70C8C017FE47Q41509005-CB713F92-2B33-4D19-A519-42E02B9F15E0Q41853206-289351EE-5E4B-4F60-97D0-91A6CBD24E64Q42317631-81AC22D7-2CE6-477B-BF68-0F8D2AD8E4F1Q42362818-A463B5D7-9A96-480A-952E-EBCCDAF0B0F6Q42376928-F1854D81-1E02-4633-BB6A-D3D7E302A3DDQ43127358-59A01EE4-349D-47E5-8EA7-00064934D2EE
P2860
Pharmacokinetic changes during extracorporeal membrane oxygenation: implications for drug therapy of neonates.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Pharmacokinetic changes during ...... for drug therapy of neonates.
@ast
Pharmacokinetic changes during ...... for drug therapy of neonates.
@en
type
label
Pharmacokinetic changes during ...... for drug therapy of neonates.
@ast
Pharmacokinetic changes during ...... for drug therapy of neonates.
@en
prefLabel
Pharmacokinetic changes during ...... for drug therapy of neonates.
@ast
Pharmacokinetic changes during ...... for drug therapy of neonates.
@en
P1476
Pharmacokinetic changes during ...... for drug therapy of neonates.
@en
P2093
Marcia L Buck
P304
P356
10.2165/00003088-200342050-00001
P577
2003-01-01T00:00:00Z
P6179
1006056958